An analysis of original research contributions toward FDA-approved drugs.
Drug Discov Today
; 20(10): 1182-7, 2015 Oct.
Article
em En
| MEDLINE
| ID: mdl-26113307
ABSTRACT
Academic researchers shaped the landscape of drug discovery for nearly two centuries, and their efforts initiated programs for more than half of the US Food and Drug Administration (FDA)-approved new molecular entities (NMEs). During the first 50 years of the 20th century, contributions from industry-based discovery programs steadily increased, stabilizing near half of all first publications for NMEs. Although academia and industry have made similar contributions to the discovery of FDA-approved NMEs, there remains a substantial difference in the gap-to-approval; on average, industry NMEs are 12 years closer to market at the time of the first publication. As more drug discovery efforts shift from industry to academia, including high-throughput screening resources, academia could have an increasingly crucial role in drug discovery.
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Aprovação de Drogas
/
Indústria Farmacêutica
/
Descoberta de Drogas
Limite:
Humans
País como assunto:
America do norte
Idioma:
En
Ano de publicação:
2015
Tipo de documento:
Article